JP2022520080A5 - - Google Patents

Info

Publication number
JP2022520080A5
JP2022520080A5 JP2021546888A JP2021546888A JP2022520080A5 JP 2022520080 A5 JP2022520080 A5 JP 2022520080A5 JP 2021546888 A JP2021546888 A JP 2021546888A JP 2021546888 A JP2021546888 A JP 2021546888A JP 2022520080 A5 JP2022520080 A5 JP 2022520080A5
Authority
JP
Japan
Application number
JP2021546888A
Other languages
Japanese (ja)
Other versions
JP2022520080A (ja
JPWO2020168051A5 (https=
JP7586601B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018073 external-priority patent/WO2020168051A1/en
Publication of JP2022520080A publication Critical patent/JP2022520080A/ja
Publication of JPWO2020168051A5 publication Critical patent/JPWO2020168051A5/ja
Publication of JP2022520080A5 publication Critical patent/JP2022520080A5/ja
Priority to JP2024193416A priority Critical patent/JP2025032080A/ja
Application granted granted Critical
Publication of JP7586601B2 publication Critical patent/JP7586601B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546888A 2019-02-13 2020-02-13 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 Active JP7586601B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024193416A JP2025032080A (ja) 2019-02-13 2024-11-05 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962805271P 2019-02-13 2019-02-13
US62/805,271 2019-02-13
US201962850919P 2019-05-21 2019-05-21
US62/850,919 2019-05-21
US201962852224P 2019-05-23 2019-05-23
US201962852228P 2019-05-23 2019-05-23
US62/852,228 2019-05-23
US62/852,224 2019-05-23
US201962873138P 2019-07-11 2019-07-11
US62/873,138 2019-07-11
US201962888867P 2019-08-19 2019-08-19
US62/888,867 2019-08-19
US201962931722P 2019-11-06 2019-11-06
US62/931,722 2019-11-06
US201962941569P 2019-11-27 2019-11-27
US62/941,569 2019-11-27
US202062966526P 2020-01-27 2020-01-27
US62/966,526 2020-01-27
PCT/US2020/018073 WO2020168051A1 (en) 2019-02-13 2020-02-13 Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193416A Division JP2025032080A (ja) 2019-02-13 2024-11-05 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法

Publications (4)

Publication Number Publication Date
JP2022520080A JP2022520080A (ja) 2022-03-28
JPWO2020168051A5 JPWO2020168051A5 (https=) 2023-02-21
JP2022520080A5 true JP2022520080A5 (https=) 2023-02-21
JP7586601B2 JP7586601B2 (ja) 2024-11-19

Family

ID=72045106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546888A Active JP7586601B2 (ja) 2019-02-13 2020-02-13 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法
JP2024193416A Pending JP2025032080A (ja) 2019-02-13 2024-11-05 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024193416A Pending JP2025032080A (ja) 2019-02-13 2024-11-05 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法

Country Status (8)

Country Link
US (1) US20230140953A1 (https=)
EP (1) EP3924484A4 (https=)
JP (2) JP7586601B2 (https=)
KR (1) KR20210127206A (https=)
CN (2) CN119280261A (https=)
AU (1) AU2020223306A1 (https=)
CA (1) CA3128876A1 (https=)
WO (1) WO2020168051A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3765615T3 (pl) 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
US12522812B2 (en) 2018-05-16 2026-01-13 Arbor Biotechnologies, Inc. CRISPR-associated systems and components
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
US20220235347A1 (en) 2019-02-13 2022-07-28 Beam Therapeutics Inc. Compositions and methods for treating hemoglobinopathies
WO2020168122A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
KR102851101B1 (ko) 2019-04-15 2025-08-27 에디진 테라퓨틱스(베이징) 인크. Rna를 편집하기 위한 방법 및 조성물
PE20220300A1 (es) 2019-07-12 2022-03-09 Univ Beijing Edicion de acido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actua sobre acido ribonucleico endogeno (adar) utilizando acidos ribonucleicos (arn) modificados geneticamente
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
IL294201A (en) * 2019-12-30 2022-08-01 Edigene Therapeutics Beijing Inc A method based on leaper technology to treat mps ih and a preparation
CA3170326A1 (en) * 2020-02-13 2021-08-19 Beam Therapeutics Inc. Compositions and methods for engraftment of base edited cells
WO2022027035A1 (en) * 2020-07-27 2022-02-03 The Children's Hospital Of Philadelphia In utero and postnatal gene editing and therapy for treatment of monogenic diseases, including mucopolysaccharidosis type 1h and other disorders
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
CA3196425A1 (en) * 2020-10-21 2022-04-28 Jin Billy Li A screening platform for adar-recruiting guide rnas
WO2022221699A1 (en) * 2021-04-16 2022-10-20 Beam Therapeutics, Inc. Genetic modification of hepatocytes
WO2022241270A2 (en) * 2021-05-14 2022-11-17 Beam Therapeutics Inc. Compositions and methods for treating transthyretin amyloidosis
WO2022246266A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
EP4426821A1 (en) * 2021-11-02 2024-09-11 University of Massachusetts Nme2cas9 inlaid domain fusion proteins
EP4441219A2 (en) * 2021-12-01 2024-10-09 Shape Therapeutics Inc. Engineered guide rnas and polynucleotides for rna editing targeting lrrk2
WO2023169454A1 (zh) * 2022-03-08 2023-09-14 中国科学院遗传与发育生物学研究所 腺嘌呤脱氨酶及其在碱基编辑中的用途
CN114686456B (zh) * 2022-05-10 2023-02-17 中山大学 基于双分子脱氨酶互补的碱基编辑系统及其应用
KR20250067157A (ko) * 2022-09-08 2025-05-14 더 유니버시티 코트 오브 더 유니버시티 오브 에딘버그 레트 증후군 요법
WO2024230760A1 (zh) * 2023-05-09 2024-11-14 北京齐禾生科生物科技有限公司 一种可作用于dna的腺苷脱氨酶及其应用
WO2024233941A1 (en) * 2023-05-11 2024-11-14 Massachusetts Eye And Ear Infirmary Base editing approaches to treat abca4-associated stargardt disease
WO2024238623A1 (en) * 2023-05-15 2024-11-21 University Of Georgia Research Foundation, Inc. Doubly constrained peptides as allosteric inhibitors of leucine rich repeat kinase 2
CN117965505A (zh) * 2023-06-28 2024-05-03 微光基因(苏州)有限公司 工程化的腺苷脱氨酶及碱基编辑器
CN120536418A (zh) * 2024-02-26 2025-08-26 尧唐(上海)生物科技有限公司 一种脱氨酶变体、包含其的碱基编辑器及其应用
WO2025184515A1 (en) * 2024-02-29 2025-09-04 Vesigen, Inc. Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells and tissues of the eye

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130109048A1 (en) * 2010-07-09 2013-05-02 Ecole Polytechnique Federale De Lausanne (Epfl) Method for in-vitro monitoring of neuronal disorders and use thereof
ES2753391T3 (es) * 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
KR102547316B1 (ko) * 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
EP3526320A1 (en) * 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
WO2018213708A1 (en) * 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
AU2018290843B2 (en) * 2017-06-26 2025-04-24 Massachusetts Institute Of Technology CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
CN109306361B (zh) * 2018-02-11 2022-06-28 华东师范大学 一种新的a/t到g/c碱基定点转换的基因编辑系统
CN109295186B (zh) * 2018-09-30 2023-10-03 中山大学 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用

Similar Documents

Publication Publication Date Title
CN305532426S (https=)
CN305782261S (https=)
CN305606191S (https=)
CN305612576S (https=)
CN305733924S (https=)
CN305734372S (https=)
CN305736695S (https=)
CN305740790S (https=)
CN305741666S (https=)
CN305743649S (https=)
CN305744502S (https=)
CN305745260S (https=)
CN305780323S (https=)
CN305531861S (https=)
CN305782906S (https=)
CN305788556S (https=)
CN305791723S (https=)
CN305794365S (https=)
CN305798580S (https=)
CN305833069S (https=)
CN305855306S (https=)
CN305857438S (https=)
CN305860798S (https=)
CN305861761S (https=)
CN305864072S (https=)